FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Heinemann, Volker, Prof, von Weikersthal, Ludwig Fischer, MD, Decker, Thomas, MD, Kiani, Alexander, Prof, Vehling-Kaiser, Ursula, MD, Al-Batran, Salah-Eddin, Prof, Heintges, Tobias, Prof, Lerchenmüller, Christian, MD, Kahl, Christoph, MD, Seipelt, Gernot, MD, Kullmann, Frank, Prof, Stauch, Martina, MD, Scheithauer, Werner, Prof, Hielscher, Jörg, Scholz, Michael, MD, Müller, Sebastian, MD, Link, Hartmut, Prof, Niederle, Norbert, Prof, Rost, Andreas, MD, Höffkes, Heinz-Gert, Prof, Moehler, Markus, Prof, Lindig, Reinhard U, MD, Modest, Dominik P, MD, Rossius, Lisa, MD, Kirchner, Thomas, Prof, Jung, Andreas, PhD, Stintzing, Sebastian, MD
Published in The lancet oncology (01.09.2014)
Published in The lancet oncology (01.09.2014)
Get full text
Journal Article